Anti-Vascular Endothelial Growth Factor Therapeutics Industry Valued at $13.49 Billion by 2029 With CAGR of 2.3% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Anti-Vascular Endothelial Growth Factor Therapeutics Market from 2024 to 2025?
In recent years, there has been a slight expansion in the market size of anti-vascular endothelial growth factor therapeutics. The market, which is set to grow from $12.2 billion in 2024 to $12.31 billion in 2025, will have a compound annual growth rate (CAGR) of 1.0%. The escalating instances of age-related macular degeneration, a rise in diabetic retinopathy cases, advancements in the diagnosis of retinal diseases, successful clinical outcomes, efficacy, and a move towards outpatient treatment have all contributed to this historic growth period.
What Is the Projected Market Size of the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
In the coming years, the anti-vascular endothelial growth factor therapeutics market is projected to experience consistent growth. The market size is projected to reach “$13.49 billion in 2029, with a compound annual growth rate (CAGR) of 2.3%. The anticipated growth within this forecast period could be due to factors such as the rise in aging population and prevalent ocular diseases, increased use in treating retinal disorders, the advent of advanced therapeutics, greater emphasis on early intervention, global health initiatives, and improved treatment accessibility. Trends in the forecast period are likely to involve enhanced usage in cancer treatments, an emphasis on combination therapies in ophthalmology, the discovery of biosimilar versions, research into resistance mechanisms, and the incorporation of imaging technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp
Who are the Major Competitors in the Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook?
Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.
What Is Fueling Growth in the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
The rising incidence of eye-related disorders is predicted to spur the advancement of the anti-vascular endothelial growth factor (VEGF) treatments market. The term “prevalence of ophthalmic diseases” refers to the volume or ratio of people within a specific populace who are identified with or exhibit certain ocular conditions or ailments. Anti-vascular endothelial growth factor therapeutics play a vital role in decreasing the occurrence of ophthalmic diseases by efficiently addressing conditions like wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. As per World Health Organization’s report in October 2022, approximately 2.2 billion individuals globally struggle with either near or distance vision impairment and 1 billion have near or far vision impairment. Furthermore, out of these, 88.4 million have refractive error, 94 million are affected by cataracts, 8 million face age-related macular degeneration, and nearly 3.9 million exhibit diabetic retinopathy. Therefore, the surging incidence of ophthalmic diseases is propelling the growth of the anti-vascular endothelial growth factor therapeutics market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10683&type=smp
Which Anti-Vascular Endothelial Growth Factor Therapeutics Market Segments Are Growing the Fastest?
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Subsegments:
1) By Eylea: Indications, Dosage Forms
2) By Lucentis: Indications, Dosage Forms
3) By Beovu: Indications, Dosage Forms
Which Industry Trends Are Shaping the Future of the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
Innovations in therapeutic strategies stand as the trending focus in the anti-vascular endothelial growth factor therapeutics field. Companies within this market are turning to cutting-edge therapeutic methods to maintain their standing. In May 2022, for example, Ashvattha Therapeutics Inc., a clinical-stage biopharmaceutical company in the U.S, announced phase 1 safety data for healthy participants for subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema) candidates, specifically D-4517.2 therapy. This pioneer treatment was designed to cater to the unaddressed needs of DME conditions. D-4517.2 therapy is under development to allow for self-administration through an autoinjector, giving patients the ability to apply the medication on their own, once a month, within their home environment.
Access The Full Report Here:
Which Countries Are Leading the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10683
This Report Delivers Insight On:
1. How big is the anti-vascular endothelial growth factor therapeutics market, and how is it changing globally?
2. Who are the major companies in the anti-vascular endothelial growth factor therapeutics market, and how are they performing?
3. What are the key opportunities and risks in the anti-vascular endothelial growth factor therapeutics market right now?
4. Which products or customer segments are growing the most in the anti-vascular endothelial growth factor therapeutics market?
5. What factors are helping or slowing down the growth of the anti-vascular endothelial growth factor therapeutics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
